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Research
Phthalates, diesters of 1,2-benzene  dicarboxylic 
acid (phthalic acid), are a group of synthetic 
chemicals with a wide spectrum of industrial 
and commercial applications. Phthalates can 
be used as plasticizers in polyvinyl chloride 
plastics, to hold scent and as solvents in per-
sonal care products, and in food packaging 
and processing materials (Agency for Toxic 
Substances and Disease Registry 2001; Hauser 
and Calafat 2004). Data from the National 
Health and Nutrition Examination Survey 
(NHANES) show that most of the U.S. popu-
lation is exposed to phthalates [Centers for 
Disease Control and Prevention (CDC) 2005, 
2008; Silva et al. 2004a].
Some phthalates readily cross the placenta 
and are developmental and reproductive toxi-
cants in laboratory animals (Saillenfait et al. 
1998). For instance, prenatal exposure of rats 
to dibutyl phthalate (DBP) and di(2-ethyl-
hexyl) phthalate decreased fetal testis testos-
terone and insulin-like factor 3 biosynthesis 
by Leydig cells, and increased the incidence of 
cryptorchidism and hypospadias among male 
offspring (Borch et al. 2006; Gray et al. 2000; 
Parks et al. 2000). Despite evidence of wide-
spread human exposure and developmental 
toxicity, epidemiologic studies of male uro-
genital tract developmental anomalies in 
relation to prenatal exposure to phthalates 
are limited. In one of the few reports, Swan 
et al. (2005) found a decrease in anogeni-
tal distance, a marker of feminization of the 
perineum, among male infants with prenatal 
exposure to background levels of phthalates.
Low-molecular-weight phthalates [e.g., 
diethyl phthalate (DEP) and DBP] are used 
to make coatings for oral medications, includ-
ing those designed for timed release or release 
in the large bowel (Hauser and Calafat 2004; 
Koch et al. 2005). In a recent case report 
(Hauser et al. 2004), we identified one man 
with a urinary concentration of mono  butyl 
phthalate (MBP), the main DBP metabo  lite, 
that was two orders of magnitude higher than 
the 95th percentile reported in the U.S. pop-
ulation (1999–2000 NHANES). The DBP 
intake of 224.3 µg/kg/day, estimated from the 
urinary concentration of MBP (David 2000; 
Koch et al. 2003), was higher than the U.S. 
Environmental Protection Agency (EPA) ref-
erence dose (RfD) for DBP (100 µg/kg/day) 
(U.S. EPA 2008). The likely source of DBP 
exposure was Asacol (mesalamine with enteric 
coating of DBP) used to treat the patient’s 
ulcerative colitis (Hauser et al. 2004). The 
association between use of phthalate-contain-
ing medications and urinary concentrations of 
phthalate metabolites has not been explored 
for other pharmaceuticals or other specific 
phthalates. We therefore evaluated whether 
such associations may be present by using data 
from NHANES.
Materials and Methods
NHANES is a periodic health examination 
survey conducted by the National Center 
for Health Statistics (NCHS) of the CDC 
(McDowell et al. 1981; NCHS 1994). 
Respondents signed an interview consent 
form agreeing to participate, and the NCHS 
obtained institutional review board approval 
to conduct the survey. NHANES is supported 
by the U.S. government, and public-use data 
files and their documentation are available 
from the the NHANES website (NHANES 
2008).
For certain survey periods, participants 
were asked if, in the past month, they had 
taken a medication for which they needed 
a prescription. The interviewer entered the 
medi  cation name and selected the best match 
from a computerized list of prescription 
drugs. All reported medications were con-
verted to their standard generic ingredient 
name for public data release (i.e., no specific 
brand names or formulations are available). 
The interviewer also recorded the presence of 
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Ba c k g r o u n d: Widespread human exposure to phthalates, some of which are developmental and 
reproductive toxicants in experimental animals, raises concerns about potential human health risks. 
Underappreciated sources of exposure include phthalates in the polymers coating some oral medications.
oB j e c t i v e: The objective of this study was to evaluate whether users of phthalate-containing medi-
cations have higher urinary concentrations of phthalate metabolites than do nonusers.
Me t h o d s : We used publically available files from the National Health and Nutrition Examination 
Survey for the years 1999–2004. For certain survey periods, participants were asked to recall use 
of prescription medication during the past 30 days, and for a subsample of individuals, the urinary 
concentrations of phthalate metabolites were measured. We a priori identified medications poten-
tially containing phthalates as inactive ingredients and then compared the mean urinary concentra-
tion of phthalate metabolites between users and nonusers of those medications.
re s u l t s: Of the 7,999 persons with information on urinary phthalate concentrations, 6 reported 
using mesalamine formulations, some of which may include dibutyl phthalate (DBP); the mean 
urinary concentration of monobutyl phthalate, the main DBP metabolite, among these mesalamine 
users was 50 times higher than the mean for nonusers (2,257 µg/L vs. 46 µg/L; p < 0.0001). Users 
of didanosine, omeprazole, and theophylline products, some of which may contain diethyl phthalate 
(DEP), had mean urinary concentrations of monoethyl phthalate, the main DEP metabolite, signifi-
cantly higher than the mean for nonusers.
co n c l u s i o n: Select medications might be a source of high exposure to some phthalates, one of 
which, DBP, shows adverse developmental and reproductive effects in laboratory animals. These 
results raise concern about potential human health risks, specifically among vulnerable segments of 
the general population and particularly pregnant women and children.
key w o r d s : coating, didanosine, medications, mesalamine, omeprazole, phthalates, theophylline. 
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the container during the home interview and 
asked, “For how long have you been taking it?” 
Although questions about non  prescription pain 
relief medicines were asked in the analgesics 
sub  section during certain periods, neither the 
specific brand names for analgesics nor infor-
mation on other non  prescription medications 
were recorded.
For each survey cycle, urine samples 
were collected from a one-third sub  sample 
of individuals ≥ 6 years of age. Since 1999, 
the urinary concentrations of several phtha-
late metabolites have been measured at the 
National Center for Environmental Health 
using solid-phase extraction coupled to 
high-performance liquid chromatography–
isotope dilution tandem mass spectrometry, 
as described previously (Blount et al. 2000; 
Kato et al. 2005; Silva et al. 2004a, 2004b). 
The phthalate metabolites for which uri-
nary concentration data are available since 
1999 are monoethyl phthalate (MEP), 
MBP, mono  cyclohexyl phthalate (MCHP), 
mono(2-ethyl  hexyl) phthalate, mono-n-
octyl phthalate (MOP), monobenzyl phtha-
late, and mono  isononyl phthalate (MNP). 
Urinary concentrations of additional metabo-
lites became available during later survey years. 
For example, the urinary concentrations of 
mono(3-carboxy  propyl) phthalate (MCPP), 
mono  isobutyl phthalate, mono(2-ethyl-5-
hydroxy  hexyl) phthalate, mono(2-ethyl-5-
oxyhexyl), and mono  methyl phthalate have 
been meas  ured since 2001, and of mono-(2-
ethyl-5-carboxy  pentyl) phthalate since 2003. 
We do not present MCHP, MOP, and MNP 
data because these metabolites were infre-
quently detected (< 20% of the samples). For 
concentrations below the limit of detection 
(LOD), we imputed a value equal to the 
LOD/√
⎯
2 (Hornung and Reed 1990).
We estimated the daily exposure to DBP 
from the urinary concentrations of MBP 
using the method proposed by David (2000), 
as expressed by Koch et al. (2003):
  DI = [(ME × CE)/(FUE × 1,000)]  
    × ( MWd/MWm),  [1]
where DI is the daily intake in milligrams 
per kilogram per day; ME is the creatinine-
corrected urinary metabolite concentration 
in micrograms per gram; CE is the creatinine 
clearance rate, normalized for body weight, in 
milligrams per kilogram per day; FUE is the 
molar conversion factor that relates urinary 
excretion of metabolite to diester ingested; and 
MWd and MWm are the molecular weights of 
diester and metabolite, respectively. For these 
calculations, we set CE at 20 mg/kg/day for 
adults and used the 0.69 reported for MEP/
DEP as the FUE value (David 2000; Koch 
et al. 2003).
For the present analyses, we used three 
files from NHANES 1999–2004 (NHANES 
2008): a) sample demographics file, which pro-
vides selected demographic variables such as 
sex and age; b) the prescription medication 
section of the Sample Person Questionnaire; 
and c) the urinary phthalates laboratory files, 
which include data on urinary concentrations 
of specific phthalate metabolites. These files 
were linked using the unique survey partici-
pant identifier number (NHANES 2005). 
Because only survey participants ≥ 6 years of 
age were eligible for the laboratory subsections, 
we restricted the analyses presented below to 
persons ≥ 6 years of age.
We had a priori identified medications that 
may contain phthalates as inactive ingredients 
using publically available sources. We first 
created a list of medications of interest based 
on their likelihood of containing phthalates 
[e.g., the 2006 Red Book list of “Drugs That 
Should Not Be Crushed” (Thomson PDR 
2006)] and then obtained detailed information 
on their formulations, following a thorough 
strategy that ranged from searching Food and 
Drug Administration websites and product 
labels to direct requests to manufacturers of 
both medications and phthalates. Given the 
limited data available in NHANES, we had 
to restrict the scope of the analysis to phtha-
late-containing prescription medications for 
which we were able to identify users in the 
study population. Further, because only some 
brands with a given active ingredient might 
contain phthalates, we selected medications 
for which phthalate-containing brand(s) were 
likely to account for a high proportion of use 
for the specific active ingredient. Based on the 
above exclusions, from a list of 47 medica-
tions that may contain phthalates, we a priori 
selected 4 for evaluation: a) mesalamine [DBP 
is contained in Asacol (Procter & Gamble 
Pharmaceuticals, Cincinnati, OH)]; b) didanos-
ine [DEP in Videx EC (Bristol Myers Squibb, 
Princeton, NJ)]; c) omeprazole [DEP in Prilosec 
(AstraZeneca, Wilmington, DE), and perhaps 
in generic versions there are unidentified high-
molecu  lar-weight phthalates such as diiso-
octyl, diisononyl, and diisodecyl phthalate]; 
and d) theophylline [DEP in Theo-Dur and 
Uni-dur (Key Pharmaceuticals, Denilworth, 
NJ), and perhaps unidentified high-molecular-
weight phthalates in generic versions].
We compared the mean urinary concen-
trations of each specific phthalate metabolite 
among users and nonusers of these medica-
tions. For medications with < 10 users, we used 
the Wilcoxon test for the crude comparison 
and also conducted a matched analysis by com-
paring each exposed subject with 5 randomly 
selected unexposed subjects matched on sex, 
age, race, and NHANES survey cycle. For more 
commonly used medi  cations, we used linear 
regression models, both crude and adjusted for 
sex, age, race, and NHANES survey cycle. Use 
of sampling weights (NCHS 2007), transfor-
mation of phthalate metabolite concentrations 
using a natural logarithm, or adjustment for 
creatinine concentrations resulted in virtually 
the same results. All analy  ses were performed 
using SAS for Windows, version V.9.1 (SAS 
Institute Inc., Cary, NC).
Results
Of the 31,112 individuals who responded to the 
demographic questionnaire, 7,999 had infor-
mation on urinary phthalate concentrations. 
Table 1. Demographic characteristics of users and nonusers of specific phthalate-containing medications, 
NHANES 1999–2004.
  Total  Medication [n (%)]
Characteristic  no.  Mesalamine  Didanosine  Omeprazole  Theophylline
Total  7,996  6 (0.08)  3 (0.04)  91 (1.14)  27 (0.34)
Age (years)
  < 16  2,219  0 (0)  0 (0)  1 (0.05)  0 (0)
  16–30  2,081  2 (0.10)  0 (0)  7 (0.34)  0 (0)
  31–50  1,596  3 (0.19)  2 (0.13)  22 (1.38)  5 (0.31)
  > 50  2,100  1 (0.05)  1 (0.05)  61 (2.90)  22 (1.05)
Sex
  Male  3,867  4 (0.10)  3 (0.08)  48 (1.24)  14 (0.36)
  Female  4,129  2 (0.05)  0 (0)  43 (1.04)  13 (0.31)
  Pregnant  319  1 (0.31)    2 (0.63)  0 (0)
  Not pregnant  2,247  1 (0.04)    14 (0.62)  5 (0.22)
  Pregnancy unknown  176  0 (0)    2 (1.14)  2 (1.14)
  Missing  1,387  0 (0)    25 (1.80)  6 (0.43)
Race
  Mexican  2,154  1 (0.05)  2 (0.09)  11 (0.51)  4 (0.19)
  Other Hispanic  352  0 (0)  0 (0)  4 (1.14)  1 (0.28)
  Non-Hispanic white  3,212  4 (0.12)  0 (0)  58 (1.81)  17 (0.53)
  Non-Hispanic black  1,983  0 (0)  1 (0.05)  13 (0.66)  5 (0.25)
  Other  295  1 (0.34)  0 (0)  5 (1.69)  0 (0)
Education
  < High school  4,507  0 (0)  0 (0)  33 (0.73)  10 (0.22)
  High school  1,271  2 (0.16)  0 (0)  22 (1.73)  8 (0.63)
  > High school  2,206  4 (0.18)  3 (0.14)  35 (1.59)  9 (0.41)
  Refused/unknown  12  0 (0)  0 (0)  1 (8.33)  0 (0)Phthalates in medications
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Overall, use of phthalate-containing medica-
tions increased with age and was similar for 
males and females; at least three exposed women 
were pregnant (Table 1).
Six subjects reported use of mesala-
mine; their individual MBP concentrations 
were 4,691, 4,358, 3,191, 1,055, 185, and 
59 µg/L, and their corresponding creatinine-
adjusted concentrations were 6,426, 4,150, 
1,707, 1,160, 110, and 29.4 µg/g creati-
nine. The corresponding estimated doses of 
DBP for these six persons were 233, 151, 
62, 42, 4, and 1 µg/kg/day. Thus, two of the 
six individuals exceeded the upper limit of 
the U.S. EPA RfD for DBP of 100 µg/kg/
day (U.S. EPA 2008), including a woman of 
childbearing age. The mean MBP concentra-
tion for mesalamine users was 2,257 µg/L, 
50 times higher than the mean for non  users 
(p < 0.0001); the mean concentrations of 
MCPP, a minor metabolite of DBP and also 
a metabolite of some other high-molecular-
weight phthalates (Calafat et al. 2006), was 
about 10 times higher (Table 2). Compared 
with the 30 matched controls, for whom the 
mean MBP concentration was 24 µg/L, the 
mean MBP concentration for mesalamine 
users was almost 100 times higher (p < 0.001), 
and the mean concentration of MCPP was 
also higher (53 vs. 5 µg/L; p < 0.001).
As shown in Table 1 and Figure 1, users 
of didanosine, omeprazole, and theophylline 
had significantly higher urinary concentrations 
of MEP than did nonusers. For didano  sine, 
the individual MEP concentrations for the 
three users were 11,950, 1,764, and 265 µg/L. 
The mean MEP concentration among didano-
sine users was 4,660 µg/L, substantially higher 
than the corresponding mean among the 
15 matched controls (740 µg/L; p = 0.139). 
Mean concentrations of MCPP were also 
higher among users of omeprazole and theo-
phylline compared with non  users. For omepra-
zole and theophylline, crude and adjusted 
analyses gave similar results. Overall, the dif-
ferences in mean concentrations for these two 
medications were due to a few exposed subjects 
with very high MEP concentrations rather 
than to an upward shift in the concentrations 
for all users. For omeprazole, 45% of users had 
MEP concentrations below the 50th percentile 
in the population, but 11% were above the 
95th percentile (2,628 µg/L), with individual 
MEP concentrations of 4,219, 4,334, 4,821, 
5,770, 6,242, 7,510, 8,374, 9,841, 11,159, 
and 18,292 µg/L. For theophylline, 37% of 
users had MEP concentrations below the 50th 
percentile in the population, but 22% were 
above the 95th percentile, with individual 
MEP concentrations of 5,101, 5,770, 10,096, 
11,507, 12,821, and 23,810 µg/L.
The higher mean MEP concentration 
observed among mesalamine users was com-
pletely attributable to one patient taking 
theophylline and mesalamine simultaneously. 
Of note, urinary metabolite concentrations 
for phthalates not known to be included in 
the study medications did not differ between 
users and nonusers.
The interviewer observed the medicine 
container for all users of mesalamine and 
didanosine, and for most users of omeprazole 
(82.4%) and theophylline (81.5%); for the 
few subjects whose container was not seen at 
interview, phthalate metabolite urinary con-
centrations were elevated. All users of mesala-
mine, didanosine, and theophylline had been 
on the medication for at least 1 month. Two 
subjects had used omeprazole for < 1 week; 
their MEP concentrations were more than 
twice the average in the population.
Discussion
Using data from NHANES 1999–2004, we 
confirmed the observation from an earlier 
case report (Hauser et al. 2004) that urinary 
concentrations of MBP, the major metabolite 
of DBP contained in Asacol, are significantly 
higher among users of mesalamine compared 
with nonusers. Four of six mesalamine users 
had estimated DBP intakes above or close to 
the upper limit of the doses suggested to be safe 
for the human population. Only one mesala-
mine user had urinary concentrations of MBP 
Table 2. Number of exposed persons, mean urinary concentrations of phthalate metabolites (µg/L), and 
percentage of subjects above the 95th percentile (> 95th pct) in users of specific phthalate-containing 
medications and in nonusers, NHANES 1999–2004.
  Users of phthalate-containing medicationa
Metabolite  Nonusers  Mesalamine  Didanosine  Omeprazole  Theophylline
MBP
  No.  7,874  6  3  91  27
  Mean  46.1  2,257**  16.8  28.2  199b
  > 95th pct  5%  83%  0%  2%  7%
MCPP
  No.  5,365  6  2  54  16
  Mean  5.3  52.6**  1.7  41.7**  44.6b**
  > 95th pct  5%  67%  0%  35%  25%
MiBP
  No.  5,365  6  2  54  16
  Mean  7.4  6.5  3.5  3.5  5.5
  > 95th pct  5%  0%  0%  0%  6%
MEP 
  No.  7,874  6  3  91  27
  Mean  653  2,390b  4,660*  1,210*  2,924**
  > 95th pct  5%  33%  33%  11%  22%
MEHP
  No.  7,874  6  3  91  27
  Mean  9.3  12.2  14.5  5.6  4.7
  > 95th pct  5%  0%  0%  3%  0%
MEHHP
  No.  5,365  6  2  54  16
  Mean  57.9  82.3  10.8  32.3  50.5
  > 95th pct  5%  17%  0%  4%  6%
MEOHP
  No.  5,365  6  2  54  16
  Mean  37.3  50  5.6  20  34.2
  > 95th pct  5%  17%  0%  4%  6%
MECCP
  No.  2,613  4  0  21  7
  Mean  86.5  113.5  NA  35  45.5
  > 95th pct  5%  25%     0%  0%
MBzP
  No.  7,874  6  3  91  27
  Mean  37  16.5  22.4  24.8  22.3
  > 95th pct  5%  0%  0%  4%  4%
MMP
  No.  5,365  6  2  54  16
  Mean  5.3  2.9  4.2  5  2.1
  > 95th pct  5%  0%  0%  9%  0%
Phthalates: MBP (n = 7,999); MiBP, mono-isobutyl phthalate (n = 5,439); MCPP (n = 5,439); MEP (n = 7,999); MEHP, mono-
(2-ethylhexyl) phthalate (n = 7,999); MEHHP, mono-(2-ethyl-5-hydroxyhexyl) phthalate, (n = 5,439); MEOHP, mono-(2-ethyl-
5-oxohexyl) phthalate, (n = 5,439); MECCP, mono-(2-ethyl-5-carboxypentyl) phthalate (n = 2,645); MBzP, mono-benzyl 
phthalate, (n = 7,999); MMP, mono-methyl phthalate, (n = 5,439). Sample sizes vary because not all phthalate metabolites 
were measured throughout the study period.
ap-Values from Wilcoxon test for mesalamine and didanosine and from linear regression models adjusted for creatinine, 
sex, age, NHANES cycle, mesalamine, and theophylline for omeprazole and theophylline. bThe differences in the mean 
MEP concentrations for mesalamine and MBP concentrations for theophylline are completely accounted for by one 
patient taking theophylline and mesalamine simultaneously. This patient was excluded from the MEP analysis for mesala-
mine and from the MBP and MCPP analyses for theophylline. *p ≤ 0.05. **p ≤ 0.001.Hernández-Díaz et al.
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below the 95th percentile for the NHANES 
1999–2004 population, which could possibly 
be explained by use of a medication containing 
mesalamine but not DBP (i.e., not Asacol). 
Alternatively, because the elimination half-life 
of DBP is measured in hours, if the patient 
missed any doses the days before the sample 
collection, the urinary concentrations of MBP 
would be expected to return rapidly to back-
ground levels (Koch et al. 2005). In addition, 
we found elevated urinary concentrations 
of MEP associated with use of didanosine, 
omeprazole, and theophylline—products that 
might contain the parent phthalate, DEP. The 
high MCPP concentrations found for some 
omeprazole and theophylline users might result 
from exposure to dioctyl phthalate or other 
unidentified high-molecular-weight phthalates 
(Calafat et al. 2006) potentially used in some 
formulations or packaging. The elevated lev-
els found in two subjects who had been using 
omeprazole for less than 1 week suggest that 
just a few doses of this medication were enough 
to result in detectable elevations.
Of note, we found high urinary concentra-
tions only for the metabolites of the phtha-
late diesters that might be present as inactive 
ingredients. Although all differences were sta-
tistically significant, the 50-fold difference for 
mesalamine was considerably larger than that 
for the other medications. Potential expla-
nations include the following: a) patients 
with inflammatory bowel disease might have 
increased intestinal absorption of phtha-
lates; b) Asacol is typically taken in doses of 
6–12 tablets a day; c) the doses of phthalates 
per tablet might be higher in Asacol than in 
other medications; and d) most of the mesala-
mine use may have come from brands that 
contain DBP. The last explanation is consis-
tent with the high MEP concentrations found 
for only some of the patients exposed to other 
medications, because presumably only some of 
the brands would have contained DEP.
Our study is limited by the inexact meas-
ures of medication use and subsequent likely 
misclassification of phthalate exposure. In addi-
tion to lacking information on dose and subject 
adherence, our data did not include informa-
tion on brand names, so we could not restrict 
our assessment to active ingredients that also 
included a phthalate; rather, we only know that 
the active ingredient reported in the NHANES 
data could, in some formulations, contain a 
phthalate. Thus, we included as exposed those 
subjects who might have stopped their medica-
tions days before the urine sample collection or 
used a formulation or brand without phthalates 
or at least without the phthalates identified in 
this study. The finding of a few exposed sub-
jects with very high phthalate concentrations 
rather than a generalized elevation for all users 
supports the likelihood that we incorrectly clas-
sified some non  exposed subjects as exposed. As 
a result, the associations we observed probably 
underestimate the true impact of exposure to 
phthalates in medications.
The present data suggest that certain medi-
cations can be an important source of exposure 
to some phthalates and that exposures from 
medications can far exceed population levels 
from various other sources. If our findings are 
confirmed, future risk assessments of environ-
mental exposures to phthalates might need 
to consider high phthalate exposure in sub-
jects on some of these medications. In some 
instances, medication use may contribute to 
human exposures that exceed the U.S. EPA 
RfDs (U.S. EPA 2008). Further exploration 
and consideration of the contribution of medi-
cations to phthalate exposure are warranted 
because of the potential for high delivered 
doses of phthalates to vulnerable segments of 
the population, particularly pregnant women 
or young children (Marsee et al. 2006).
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